SNGX SOLIGENIX, INC.

BEARISH Impact: 6/10 EFFECT
Horizon days Filed Apr 3, 2026 Processed 1mo ago SEC 9999999995-26-001064
Latest settled — T+20d
SNGX ▼ -69.30% at T+20d
SHORT call ✓ call won +69.30% · α vs SPY +78.28% · entry $1.14 → $0.3500
Next anchor: T+60d in 5w
Last close $0.3900 (close May 22) · +65.79% from $1.14 entry (call sign-flipped)
Entry anchored
Apr 2, 03:59 PM ET
via Databento tick
T+1d
0.00%
call 0.00% · α +0.06%
$1.14
settled 7w ago
T+5d
+0.88%
call -0.88% · α +3.26%
$1.15
settled 6w ago
T+20d
-69.30%
call +69.30% · α +78.28%
$0.3500
settled 23d ago
T+60d
—
call — · α —
—
in 5w

Price Chart

Loading chart...

Executive Summary

Soligenix, Inc. (SNGX) has had four separate shelf registration statements (Forms S-3) become effective, allowing the company to raise capital through future offerings of securities. The filings do not disclose specific offering sizes or terms, but signal potential dilution risk given the company's small $12M market cap.

Actionable Insight

Monitor for imminent pricing supplements or prospectus filings that will reveal offering size, price, and use of proceeds. Given the small market cap, even a modest equity raise could lead to sharp downside pressure on the stock. Consider hedging or reducing exposure ahead of any announced offering.

Key Facts

  • Four EFFECT filings were submitted on April 3, 2026, with effectiveness dated April 2, 2026.
  • Each relates to a previously filed Form S-3 shelf registration: 333-290413, 333-280993, 333-276511, and 333-271049.
  • No specific offering size, price, or security type is disclosed in the EFFECT notices.
  • Company has a market capitalization of $12M, making any future equity issuance highly dilutive.
  • Multiple concurrent effective shelf registrations suggest an aggressive capital-raising posture.

Financial Impact

Potential for significant dilution depending on future offering size and pricing.

dilutionequitymarket_cap

Risk Factors

  • Significant share dilution from upcoming equity offerings
  • Downward pressure on stock price due to supply overhang
  • Lack of transparency on use of proceeds or offering terms

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 12 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (SNGX) — Batch item 19999999995-26-001064
Document: 9999999995-26-001064-index.html9999999995-26-001059
Document: 9999999995-26-001064.txt9999999995-26-001056
EFFECT Filing (SNGX) — Batch item 49999999995-26-001059
Document: 9999999995-26-001059-index.html9999999995-26-001064
Document: 9999999995-26-001059.txt9999999995-26-001064
EFFECT Filing (SNGX) — Batch item 79999999995-26-001056
Document: 9999999995-26-001056-index.html9999999995-26-001064
Document: 9999999995-26-001056.txt9999999995-26-001064
EFFECT Filing (SNGX) — Batch item 109999999995-26-001058
Document: 9999999995-26-001058-index.html9999999995-26-001064
Document: 9999999995-26-001058.txt9999999995-26-001064

US Market Status

Market Closed — Opens Tue (34h 51m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access